Filing Details

Accession Number:
0001127602-17-020070
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-06-01 17:16:06
Reporting Period:
2017-05-30
Filing Date:
2017-06-01
Accepted Time:
2017-06-01 17:16:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1681689 Bioverativ Inc. BIVV () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1361754 J Alexander Denner C/O Bioverativ Inc.
225 Second Avenue
Waltham MA 02451
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-05-30 90,000 $55.93 1,165,000 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 5,001 Direct
Footnotes
  1. On May 30, 2017, each of Sarissa Capital Domestic Fund LP, a Delaware limited partnership ("Sarissa Domestic") and Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempt limited partnership ("Sarissa Offshore" and together with Sarissa Domestic, the "Sarissa Funds"), purchased an aggregate of 78,300 and 11,700 shares, respectively, of common stock of Bioverativ Inc.
  2. This represents the weighted average price for shares purchased at a range between $55.8993 (low) and $55.95 (high). Full information regarding the number of shares purchased at each separate price will be provided upon request by the SEC staff, the issuer or a security holder of the issuer.
  3. Includes (i) 973,771 shares beneficially owned by Sarissa Domestic and (ii) 191,229 shares beneficially owned by Sarissa Offshore.
  4. Alexander Denner, Ph.D. is the Chief Investment Officer of Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), the investment advisor to the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.